Business Profiles
Nordic Group is a privately owned pan-European pharmaceutical company with a presence in 17 countries.
It focuses on the development and commercialisation of niche hospital, and orphan products to respond to unmet medical needs. Nordic Group expertise relies on the development and sales of its own products, but also on partner products acquired at various stages of development. Portfolio of therapeutic areas: Rheumatology, critical care, woman’s health.
Business type
B2C and B2B Pharmaceutical company – produces both promoted products and generics
Core treatment areas
- Rheumatology
- Haematology
- Gynaecology
- Oncology
- Anaesthesia
- Post-natal diabetes
Product Portfolio
- iMETH
- CheckTop
- Gaviscon
- Nordimet
- Ozalin
- Metadon
- Mifegyne
- Trasylol
- Tradolan
- MisoOne
- Teysuno
- Oxycodone
- Gymiso
- Ampres
- Nasoferm
- MifeGymiso
- Tachipril
- Anagrelid
- Hyalobarrier
- InfectoFos
- Amglidia
Capabilities
- Development
- Manufacturing
- Commercial
Technology
Tablets, injections, creams, suppositories, ovules, medical devices
Corporate functions
Paris, France 
Amsterdam, Netherlands
Year of incorporation
1995
Number of employees
460
Commercial Footprint
- United Kingdom
- Switzerland
- Czech Republic
- Ireland
- Italy
- Slovakia
- France
- Spain
- Poland
- Netherlands
- Portugal
- Hungary
- Belgium
- CIS
- Romania
- Germany
- Poland
- Canada
- Austria
- Hungary
- Latin America
- Scandinavia
- Baltics
- Eastern Africa
Production Footprint
Includes Farmaprim
Amring Pharmaceuticals is devoted to offering a broad variety of products in Oncology, Women’s Health, Anesthesiology & Pain Therapy, Respiratory, Rheumatology, Gastroenterology and Post-natal Diabetes.
At Amring we are committed to helping people improve, enhance and extend their life. Amring sells uniquely positioned and harder-to-manufacture generics that bring value to customers and patients. We spend every minute of every day figuring out how to bring historically complex prescription medications to market. Our products are generics of value to the market, not high-volume, mass-produced products.
Business type
B2B Pharma Generics company with structural unmet needs (supply stability) to US institutional customers (retail, pharmacy, hospital, institution)
Treatment areas covered
- Oncology
- Women’s health
- Anesthesiology & Pain Therapy
- Gastroenterology
- Post-natal Diabetes
Product Portfolio
- Arsenic Trioxide
- Succinylcholine Chloride
- Desmopressin
- Tranexamic Acid
- Mesalamine
Capabilities
Commercialization (contracts with institutional buyers)
Technology
Currently mainly oral solids
Corporate functions
Berwyn, PA, USA
Year of incorporation
2015
Number of employees
20
Commercial Footprint
- USA
Production Footprint
N/A (working through partners)
Izvarino Pharma provides a professional and competent approach to problems of femal health.
Izvarino Pharma is a Russian pharmaceutical company founded in 2007 is focused on the production, marketing and distribution of medicinal products most demanded in the Russian market in various therapeutic areas (obstetrics and gynaecology, endocrinology, transplantation, cardiology, neurology, etc.) Today their portfolio includes more than 40 products. All products are duly registered and certified and have proven effectiveness and long-term successful application experience. The group of branded generics includes products with improved customer properties classified as generic+ products. The company operates two plants: Izvarino Pharma in Moscow and Nanopharma Development in Kazan. In addition to the manufacture of medicinal product, the company also develops innovative technologies for reduced toxicity and improved bioavailability of pharmaceutical substances.
Business type
B2B Pharma company – branded products
Reimbursable products for gov’t designated public health needs
Non-branded generics (INNs to chains)
Treatment areas covered
- Cancer
- Central nervous system
- Infections (HIV)
- Gynecology
- Endocrinology
- Cardiovascular system
Key products
- Tacrolimus
- Sibutramine
- Atorvastatin
- Abiraterone
- Mifepristone 600 mg, 200 mg, 10 mg
- Rosuvastatin
- Perindopril
- Lopinavir/Ritonavir & other HIV
- Enalapril
- Metformin
Capabilities
- Development
- Manufacturing
- Commercial
Technology
Tablets and capsules
Vials, prefilled syringes, cartridges
Corporate functions
Moscow, Russia
Year of incorporation
2007
Number of employees
410
Commercial Footprint
- Russia
Production Footprint
Izvarino and Nanopharma (Russia)
QPharma is an innovative contract developer and manufacturer of pharmaceuticals.
They offer their customers bespoke solutions through their extensive knowledge and unique manufacturing capabilities. The relatively small and flat organization and project management structure warrants efficiency in what they do and fosters good communication with their customers.
Business type
B2B contract development and manufacturing services – focus on polymer technology products, high potency actives
Core specification
Global GMP compliance: FDA, EMA, PMDA, ANVISA etc
Services portfolio
Development and manufacturing
Capabilities
- Development
- Manufacturing
- Regulatory Affairs
Technology
Polymer based dosage forms (implants, vaginal rings, IUD), solid dosage forms
Corporate functions
Malmö, Sweden
Year of incorporation
1999 (1994)
Number of employees
~290
Commercial Footprint
- Sweden
Production Footprint
Malmö, Sweden
Disphar International is fully focused on the development and licensing out of pharmaceutical products.
Disphar is there to support you with complete product solutions: from concept through to registration and supply. Disphar is your full service development partner to support your portfolio optimization.
Business type
B2B contract development and manufacturing services – focus on polymer technology products, high potency actives
Core specification
Global GMP compliance: FDA, EMA, PMDA, ANVISA etc
Services portfolio
Rediscovery of pharmaceutical products for new indications
Capabilities
- Development
- Manufacturing
- Regulatory Affairs
Technology
Polymer based dosage forms (implants, vaginal rings, IUD), solid dosage forms
Corporate functions
Baarn, Netherlands
Year of incorporation
1999 (1994)
Number of employees
~290
Commercial Footprint
- Netherlands
Production Footprint
Baarn, Netherlands